Press Release – New York, NY – February 19, 2020 – Sichenzia Ross Ference LLP announced today that it represented Aegis Capital Corp. as sole book runner in the underwritten public offering of 200,000 shares of 8% Series A Cumulative Redeemable Preferred Stock of Medalist Diversified REIT, Inc. (Nasdaq:MDRR), a real estate investment trust specializing in the acquisition, ownership and management of value-add commercial real estate. The shares were sold at an offering price of $23.00 per share for gross proceeds of $4.6 million and commenced trading on the Nasdaq Capital Market under the symbol “MDRRP.”
The Sichenzia Ross Ference LLP team was led by partners Gregory Sichenzia, Darrin Ocasio and Avital Perlman and associate Grant Levine.
SRFC is a full-service law firm with nationally recognized corporate, securities, and litigation practices that provides experienced representation in all matters involving the securities industry. In addition to handling routine to complex commercial matters, SRFC’s renowned litigation and regulatory department specializes in defending broker-dealers, registered persons, public and private corporations, and individuals in investigations and enforcement proceedings before the SEC, FINRA, and other regulatory bodies, as well as litigations and arbitrations across all forums in the securities industry, including class action lawsuits, shareholder derivative actions, and matters involving allegations of fraud, misrepresentation or other securities violations.
Latest posts by Sichenzia Ross Ference Carmel LLP (see all)
- Sichenzia Ross Ference Carmel LLP Represents Dominari Securities, Revere Securities and Pacific Century Securities in $6 Million Initial Public Offering of BUUU Group Limited - August 15, 2025
- Sichenzia Ross Ference Carmel LLP Represents RBW Capital Partners in $11.225 Million Private Placement of Digital Brands Group - August 15, 2025
- Sichenzia Ross Ference Carmel LLP Represents Laidlaw & Company and Craft Capital Management in $10 Million Initial Public Offering of Nasus Pharma - August 14, 2025
